StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Earnings

Inhibikase Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.10
-$0.13 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Inhibikase Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026after the close––-$0.10Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026during market hours–––Release
Q1 FY2026ended Mar 31, 2026May 12, 2026during market hours––-$0.10Release
Q4 FY2025ended Dec 31, 2025Mar 26, 2026during market hours–––Release
Q3 FY2025ended Sep 30, 2025Nov 14, 2025during market hours––-$0.13Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025during market hours––-$0.11Release
Q1 FY2025ended Mar 31, 2025May 14, 2025during market hours–––Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025during market hours–––Release
Q3 FY2022ended Sep 30, 2022Nov 17, 2022during market hours$7.29K–-$0.18Release
Q1 FY2021ended Mar 31, 2021Apr 1, 2021before the open–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Inhibikase Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Inhibikase Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Inhibikase Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Update
  6. News
  7. Results
  8. Update
  9. Results
  10. News
  11. Results
  12. Results
  13. Results
  14. Results
  15. Update

See a number that looks wrong?